Two doses of NGR-hTNF combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens: A phase II study.

M. Di Benedetto,E. Bennicelli,V. Andretta,A. Pessino,A. Guglielmi,M. S. Sciallero,A. Sobrero,Giuseppe Fornarini,A. Lambiase,Claudio Bordignon

Two doses of NGR-hTNF combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens: A phase II study.

2010

M. Di Benedetto
E. Bennicelli
V. Andretta
A. Pessino
A. Guglielmi
M. S. Sciallero
A. Sobrero
Giuseppe Fornarini
A. Lambiase
Claudio Bordignon

e14077 Background: NGR-hTNF consists of tumour necrosis factor (TNF) fused to the tumour homing peptide (NGR), which selectively binds an aminopeptidase N expressed on tumour blood vessels. Preclin...

Keywords:

Colorectal cancer
Phases of clinical research
NGR-hTNF
Capecitabine/oxaliplatin
Oncology
Internal medicine
Medicine
Tumor necrosis factor alpha
Aminopeptidase N
Necrosis
Homing (biology)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations